Wednesday, July 8, 2026

pharma · Idiopathic Hypersomnia · Prader-Willi Syndrome · HRMY

Harmony Biosciences Holdings

Harmony Biosciences Holdings clinical programs — 21 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

630 W. Germantown Pike, Suite 220, Plymouth Meeting, PA 19462, US HQ
2017 Founded
332 Employees
Public company Type
HRMY · NYSE Ticker
Company details
Status
Public
HQ
630 W. Germantown Pike, Suite 220, Plymouth Meeting, PA 19462, US
Founded
2017
Employees
332
Programs
21
Drugs
14
Patents
6
Intelligence · Clinical Programs

Harmony Biosciences Holdings projects

21 ClinicalTrials.gov programs sponsored by Harmony Biosciences Holdings.

Harmony Biosciences Holdings has 21 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Clemizole HCl

    Harmony Biosciences Holdings

    Lennox Gastaut Syndrome

    phase 3 small molecule active

    1 trial
  2. Clemizole HCl

    Harmony Biosciences Holdings

    Dravet Syndrome

    phase 3 small molecule active

    1 trial
  3. HBS-101-CL-312

    Harmony Biosciences Holdings

    Prader-Willi syndrome

    phase 3 small molecule active

    1 trial
  4. HBS-301 tablet

    Harmony Biosciences Holdings

    Idiopathic Hypersomnia

    phase 3 small molecule active

    1 trial
  5. Open-label pitolisant

    Harmony Biosciences Holdings

    Idiopathic Hypersomnia

    phase 3 small molecule completed

    1 trial
  6. Pitolisant

    Harmony Biosciences Holdings

    Prader-Willi Syndrome

    phase 3 small molecule active

    1 trial
  7. Pitolisant

    Harmony Biosciences Holdings

    Idiopathic Hypersomnia

    phase 3 small molecule completed

    1 trial
  8. Pitolisant tablet

    Harmony Biosciences Holdings

    Prader-Willi Syndrome

    phase 3 small molecule active

    1 trial
  9. ZYN002 Transdermal Gel Cannabidiol (CBD)

    Harmony Biosciences Holdings

    Fragile X Syndrome (FXS)

    phase 3 small molecule active

    1 trial
  10. ZYN2-CL-033

    Harmony Biosciences Holdings

    Fragile X syndrome (FXS)

    phase 3 small molecule active

    1 trial
  11. OVX836 480µg

    Harmony Biosciences Holdings

    Influenza

    phase 2 mab completed

    1 trial
  12. OVX836 shot

    Harmony Biosciences Holdings

    Vaccine-Preventable Diseases

    phase 2 mab completed

    1 trial
  13. Pitolisant Oral Tablet

    Harmony Biosciences Holdings

    Myotonic Dystrophy 1

    phase 2 small molecule completed

    1 trial
  14. Pitolisant oral tablets

    Harmony Biosciences Holdings

    Prader-Willi Syndrome

    phase 2 small molecule completed

    1 trial
  15. ZYN002

    Harmony Biosciences Holdings

    22Q11.2 Deletion Syndrome

    phase 2 small molecule completed

    1 trial
  16. HBS-201

    Harmony Biosciences Holdings

    Narcolepsy

    phase 1 small molecule completed

    1 trial
  17. MV-LASV

    Harmony Biosciences Holdings

    Lassa Virus Infection

    phase 1 mab completed

    1 trial
  18. Part 1

    Harmony Biosciences Holdings

    Drug Interaction

    phase 1 small molecule completed

    1 trial
  19. Pitolisant

    Harmony Biosciences Holdings

    Restless Legs Syndrome

    approved small molecule active

    1 trial
  20. Nutra 1-0602

    Harmony Biosciences Holdings

    Hair Thinning

    other completed

    1 trial
  21. Nutra 2-1216

    Harmony Biosciences Holdings

    Hair Thinning

    other active

    1 trial

Frequently asked questions

How many clinical projects does Harmony Biosciences Holdings have?

21 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.